Sullivan Papain Block McGrath Coffinas & Cannavo, P.C. Sullivan Papain Block McGrath Coffinas & Cannavo, P.C. Sullivan Papain Block McGrath Coffinas & Cannavo, P.C.
Call Today For a Free Consultation Call For a Free Consultation (212) 732-9000
New York Personal Injury Attorneys Click for free consultation

Product Liability

FDA Requests Removal of Ranitidine (Zantac) Products From Market for Potential Carcinogen

April 6, 2020 in
On April 1st, the Food and Drug Administration (FDA) announced its request for all prescription and over-the-counter ranitidine drugs to be removed from the market immediately. This decision was made based on an ongoing investigation of the potential risk of N-nitrosodimethylamine, or NDMA, to...
Continue Reading

Decades of Self-Regulation in the Talc-Based Consumer Product Industry Leads to More Intensive Testing by the FDA

December 17, 2019 in
After decades of lax regulation of talc-based products and cosmetics, the FDA has decided to improve testing to eliminate the risk of cancerous carcinogens in consumer goods. This issue, outlined in a recent Reuters report, brings into question the validity of self-regulation in the...
Continue Reading

Drugmaker Sanofi Issues Recall After Zantac Tests Discover Possible Carcinogen

October 22, 2019 in
As a result of FDA tests that found traces of N-nitrosodimethylamine, or NDMA, in Zantac and other forms of ranitidine, major drug manufacturer Sanofi voluntarily issued a recall of the popular heartburn medication. Here, the pharmaceutical liability attorneys at Sullivan Papain Block McGrath Coffinas...
Continue Reading

Johnson & Johnson Recalls Baby Powder After FDA Finds Traces of Asbestos

October 22, 2019 in
Johnson & Johnson has recalled 33,000 bottles of baby powder after the Food and Drug Administration (FDA) recently found asbestos in a bottle purchased online. Here, the product liability attorneys at Sullivan Papain Block McGrath Coffinas & Cannavo, P.C. discuss these latest developments. Johnson...
Continue Reading

Traces of Carcinogens Found in Generic Zantac Lead to Global Halt in Shipment

September 26, 2019 in
As a result of the discovery of the cancer-causing N-nitrosodimethylamine (NDMA) found in Zantac, manufacture and shipment of both the generic and branded forms of Zantac have been halted by Sandoz, Novartis and GlaxoSmithKline Plc. Here, the pharmaceutical liability attorneys at Sullivan, Papain, Block,...
Continue Reading